{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T01:07:26Z","timestamp":1786237646534,"version":"build-2736575974"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":371,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Describe patient characteristics, treatment patterns, clinical outcomes, healthcare resource utilization (HCRU) and medical costs associated with patients who were diagnosed with obstructive hypertrophic cardiomyopathy (HCM) in clinical practice in England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This observational, retrospective, cohort study of adults who were diagnosed with obstructive HCM in routine clinical practice in England used electronic health records from Clinical Practice Research Datalink (CPRD) GOLD\/Aurum and linked Hospital Episode Statistics (HES) databases (1 April 2007 to 30 October 2020). Adults (\u226518 years at index date) with at least one diagnosis code (ICD-10, Read, SNOMED, or OPCS) indicative of HCM with \u22651 year of continuous registration in CPRD, data of acceptable research quality and eligibility for HES linkage were included. Outcomes from the obstructive HCM cohort were stratified by New York Heart Association (NYHA) class at baseline and during follow-up. Owing to the paucity of NYHA coding, patients with obstructive HCM and no record of NYHA class were assigned a proxy NYHA classification using an algorithm that considered patient symptoms and treatments. The study included 6440 patients in the overall HCM cohort with a mean follow-up duration of 4.84 [standard deviation (SD): 2.95] years. The study population was predominantly male (61.9%) and white (79.1%), with a mean (SD) age of 61.02 (15.61) years. The proportion of patients with obstructive HCM who had a pre-specified prior medical condition relevant to understanding disease burden increased with higher NYHA class (66.5% vs. 83.0% for NYHA class I and NYHA class II+, respectively), as did the proportion of patients with at least one baseline active prescription for cardiovascular-related medication. Among patients with at least one record of a prescription for the treatment of symptomatic obstructive HCM, 41.7% experienced a treatment change during the follow-up period. Atrial fibrillation or flutter, ischaemic stroke and heart failure were the most observed clinical events among patients in the obstructive HCM cohort, and the first in-study incidence of these events increased with higher NYHA class. Total HCRU costs per patient-year increased from \u00a33033 to \u00a34517 for NYHA classes I and II+, respectively, with secondary care costs consistently being the main driver in the obstructive HCM cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Obstructive HCM is associated with a large clinical and economic burden in England, and this burden increases with higher NYHA class. These findings support the need for new and more effective strategies for the management of HCM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15213","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T01:38:47Z","timestamp":1739410727000},"page":"2034-2046","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment Patterns, Outcomes and Healthcare Resource Utilization of Obstructive Hypertrophic Cardiomyopathy in England"],"prefix":"10.1093","volume":"12","author":[{"given":"Faizel","family":"Osman","sequence":"first","affiliation":[{"name":"Institute of Cardio-Metabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust , Coventry ,","place":["UK"]},{"name":"Warwick Medical School, University of Warwick , Coventry ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla L.","family":"Zema","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hurst","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Uxbridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Sandler","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Uxbridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Brellier","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Uxbridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovie","family":"Utuama","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Kirichek","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Houghton","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lemmer","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Uxbridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite Tome","family":"Esteban","sequence":"additional","affiliation":[{"name":"Cardiovascular Clinical Academic Group, St George's Hospital NHS Foundation Trust , London ,","place":["UK"]},{"name":"St George's University of London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"2026021804242259000_ehf215213-bib-0001","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021804242259000_ehf215213-bib-0002","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cge.13027","article-title":"Genetics of hypertrophic cardiomyopathy: a review of current state","volume":"93","author":"Sabater-Molina","year":"2018","journal-title":"Clin Genet"},{"key":"2026021804242259000_ehf215213-bib-0003","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"2026021804242259000_ehf215213-bib-0004","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1161\/CIR.0b013e318223e2bd","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy","volume":"124","author":"Gersh","year":"2011","journal-title":"Circulation"},{"key":"2026021804242259000_ehf215213-bib-0005","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/s0735-1097(00)01003-2","article-title":"Sudden death in hypertrophic cardiomyopathy: identification of high risk patients","volume":"36","author":"Elliott","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026021804242259000_ehf215213-bib-0006","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"key":"2026021804242259000_ehf215213-bib-0007","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.1747","article-title":"Population estimates of obstructive and non-obstructive hypertrophic cardiomyopathy in the UK and Germany","volume":"43","author":"Schultze","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021804242259000_ehf215213-bib-0008","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jchf.2018.02.010","article-title":"Hypertrophic cardiomyopathy: clinical update. JACC","volume":"6","author":"Geske","year":"2018","journal-title":"Heart Fail"},{"key":"2026021804242259000_ehf215213-bib-0009","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s41687-020-00269-8","article-title":"Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life","volume":"4","author":"Zaiser","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2026021804242259000_ehf215213-bib-0010","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191214","article-title":"Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records","volume":"13","author":"Pujades-Rodriguez","year":"2018","journal-title":"PLoS ONE"},{"key":"2026021804242259000_ehf215213-bib-0011","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"2026021804242259000_ehf215213-bib-0012","volume-title":"ACC23 Annual Scientific Session & Expo together with World Congress of Cardiology","author":"Osman","year":"2023"},{"key":"2026021804242259000_ehf215213-bib-0013","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/13696998.2023.2277076","article-title":"Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study","volume":"26","author":"Wang","year":"2023","journal-title":"J Med Econ"},{"key":"2026021804242259000_ehf215213-bib-0014","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.1016\/j.jval.2022.09.730","article-title":"EE487 quantifying the economic burden of obstructive hypertrophic cardiomyopathy (HCM) in the UK","volume":"25","author":"Hurst","year":"2022","journal-title":"Value Health"},{"key":"2026021804242259000_ehf215213-bib-0015","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2026021804242259000_ehf215213-bib-0016","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026021804242259000_ehf215213-bib-0017","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11886-021-01600-5","article-title":"Septal ablation versus surgical myomectomy for hypertrophic obstructive cardiomyopathy","volume":"23","author":"Pelliccia","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"2026021804242259000_ehf215213-bib-0018","volume-title":"Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]. Committee Papers 2023 [updated 06 July 2023]","author":"National Institute for Health and Care Excellence"},{"key":"2026021804242259000_ehf215213-bib-0019","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/biom9120878","article-title":"Hypertrophic cardiomyopathy: an overview of genetics and management","volume":"9","author":"Teekakirikul","year":"2019","journal-title":"Biomolecules"},{"key":"2026021804242259000_ehf215213-bib-0020","volume-title":"CPRD linked data 2021 [updated 11 July 2023]","author":"Medicines and Healthcare products Regulatory Agency"},{"key":"2026021804242259000_ehf215213-bib-0021","volume-title":"Primary care data for public health research 2021 [updated 11 July 2023]","author":"Medicines and Healthcare products Regulatory Agency"},{"key":"2026021804242259000_ehf215213-bib-0022","volume-title":"National Schedule of NHS costs - Year 2019\u201320 - NHS trust and NHS foundation trusts","author":"NHS England","year":"2023"},{"key":"2026021804242259000_ehf215213-bib-0023","volume-title":"Unit Costs of Health and Social Care 2021","author":"PSSRU"},{"key":"2026021804242259000_ehf215213-bib-0024","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/hrt.42.1.35","article-title":"Treatment of hypertrophic obstructive cardiomyopathy with verapamil","volume":"42","author":"Kaltenbach","year":"1979","journal-title":"Brit Heart J"},{"key":"2026021804242259000_ehf215213-bib-0025","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1253\/jcj.47.54","article-title":"Effect of diltiazem on left ventricular isovolumic relaxation time in patients with hypertrophic cardiomyopathy","volume":"47","author":"Nagao","year":"1983","journal-title":"Jpn Circ J"},{"key":"2026021804242259000_ehf215213-bib-0026","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/0002-9149(88)90553-X","article-title":"Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy","volume":"62","author":"Sherrid","year":"1988","journal-title":"Am J Cardiol"},{"key":"2026021804242259000_ehf215213-bib-0027","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026021804242259000_ehf215213-bib-0028","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021804242259000_ehf215213-bib-0029","volume-title":"FDA approves new drug to improve heart function in adults with rare heart condition 2022","author":"U.S Food and Drug Administration"},{"key":"2026021804242259000_ehf215213-bib-0030","volume-title":"CHMP summary of positive opinion for Camzyos 2023 [updated 11 July 2023]","author":"European Medicines Agency"},{"key":"2026021804242259000_ehf215213-bib-0031","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.amjmed.2015.07.035","article-title":"Misconceptions and facts about hypertrophic cardiomyopathy","volume":"129","author":"Argulian","year":"2016","journal-title":"Am J Med"},{"key":"2026021804242259000_ehf215213-bib-0032","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"2026021804242259000_ehf215213-bib-0033","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40119-022-00257-7","article-title":"Treatment changes, healthcare resource utilization, and costs among patients with symptomatic obstructive hypertrophic cardiomyopathy: a claims database study","volume":"11","author":"Owens","year":"2022","journal-title":"Cardiol Ther"},{"key":"2026021804242259000_ehf215213-bib-0034","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jjcc.2022.09.015","article-title":"Estimating the prevalence, clinical characteristics, and treatment patterns of hypertrophic cardiomyopathy in Japan: a nationwide medical claims database study","volume":"81","author":"Terasaka","year":"2023","journal-title":"J Cardiol"},{"key":"2026021804242259000_ehf215213-bib-0035","volume-title":"Therapeutic Goods Administration. RYTHMODAN disopyramide 100mg Capsules BP (Canada)","author":"Department of Health and Aged Care"},{"key":"2026021804242259000_ehf215213-bib-0036","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026021804242259000_ehf215213-bib-0037","doi-asserted-by":"publisher","volume-title":"Outcomes by New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy. American College of Cardiology's Annual Scientific Session & Expo 2022; April 2\u20134, 2022; Washington, DC","author":"Wang","DOI":"10.1111\/jre.13382"},{"key":"2026021804242259000_ehf215213-bib-0038","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12955-020-01604-9","article-title":"Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire","volume":"18","author":"Capota","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2026021804242259000_ehf215213-bib-0039","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/13696998.2021.1978242","article-title":"Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States","volume":"24","author":"Jain","year":"2021","journal-title":"J Med Econ"},{"key":"2026021804242259000_ehf215213-bib-0040","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.amjcard.2022.12.030","article-title":"Clinical outcomes, resource utilization, and treatment over the disease course of symptomatic obstructive hypertrophic cardiomyopathy in the United States","volume":"192","author":"Desai","year":"2023","journal-title":"Am J Cardiol"},{"key":"2026021804242259000_ehf215213-bib-0041","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.1016\/S2666-7568(24)00108-9","article-title":"The economic burden of cancer, coronary heart disease, dementia, and stroke in England in 2018, with projection to 2050: an evaluation of two cohort studies","volume":"5","author":"Landeiro","year":"2024","journal-title":"Lancet Healthy Longev"},{"key":"2026021804242259000_ehf215213-bib-0042","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ehjqcco\/qcaa093","article-title":"Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs","volume":"8","author":"Burdett","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026021804242259000_ehf215213-bib-0043","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.1747","article-title":"Population estimates of obstructive and non-obstructive hypertrophic cardiomyopathy in the UK and Germany","volume":"43","author":"Schultze","year":"2022","journal-title":"Eur Heart J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/2034\/66955969\/eschf_12_3_2034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/2034\/66955969\/eschf_12_3_2034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:24:28Z","timestamp":1771406668000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/3\/2034\/8488315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2,12]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15213","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"2024-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}